Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GE stock price vs MRNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRNA's multiple
Needs MRNA P/E.
Implied fair value · at GE's multiple
Needs Annual EPS is negative, GE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GENERAL ELECTRIC CO · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MORGAN STANLEY
GE vs MS
EMERSON ELECTRIC CO
GE vs EMR
3M CO
GE vs MMM
CUMMINS INC
GE vs CMI
HONEYWELL INTERNATIONAL INC
GE vs HON
LOCKHEED MARTIN CORP
GE vs LMT
PFIZER INC
GE vs PFE
JOHNSON & JOHNSON
GE vs JNJ
GILEAD SCIENCES, INC.
GE vs GILD
AMGEN INC
GE vs AMGN
NOVAVAX INC
GE vs NVAX
VERTEX PHARMACEUTICALS INC / MA
GE vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GE can sustain its 18.5% revenue growth and 31.4% ROIC, then GE looks attractive versus MRNA because its profitability and valuation both exceed MRNA's on the provided data.
GE's current price of $368.93 sits below MRNA-implied value of $495.09, implying 34.2% upside. The gap is supported by GE trading at lower P/S and EV/Revenue multiples than MRNA despite far better profitability and growth.
Supporting Metrics
